Ruthenium(III) maltolato-nitroimidazole complexes: synthesis and biological activity.

[1]  B. Patrick,et al.  Tris(pyronato)- and tris(pyridonato)-ruthenium(III) complexes and solution NMR studies. , 2005, Inorganic chemistry.

[2]  B. Patrick,et al.  Ruthenium(II) sulfoxide-maltolato and -nitroimidazole complexes: synthesis and MTT assay. , 2003, Inorganic chemistry.

[3]  B. Patrick,et al.  The synthesis, structural characterization, and in vitro anti-cancer activity of chloro( p -cymene) complexes of ruthenium(II) containing a disulfoxide ligand , 2003 .

[4]  A. Bergamo,et al.  Tumour cell uptake of the metastasis inhibitor ruthenium complex NAMI-A and its in vitro effects on KB cells , 2002, Cancer Chemotherapy and Pharmacology.

[5]  J. Cummings,et al.  In vitro and in vivo activity and cross resistance profiles of novel ruthenium (II) organometallic arene complexes in human ovarian cancer , 2002, British Journal of Cancer.

[6]  J. Cummings,et al.  Inhibition of cancer cell growth by ruthenium(II) arene complexes. , 2001, Journal of medicinal chemistry.

[7]  C. Anderson.  Synthesis of chloro(2-methylimidazole) ruthenium(III) complexes and their aqueous solution chemistry, and the crystal structure of [2-MeImH]2[RuCl52-MeIm] , 2001 .

[8]  M. Gross,et al.  Differentiation of positional isomers of nitro meso-tetraphenylporphyrins by tandem mass spectrometry , 2001, Journal of the American Society for Mass Spectrometry.

[9]  R. Muschel,et al.  The farnesyltransferase inhibitor L744,832 reduces hypoxia in tumors expressing activated H-ras. , 2001, Cancer research.

[10]  A. Bergamo,et al.  Ruthenium-based compounds and tumour growth control (review). , 2000, International journal of oncology.

[11]  J. G. Haasnoot,et al.  Strong differences in the in vitro cytotoxicity of three isomeric dichlorobis(2-phenylazopyridine)ruthenium(II) complexes. , 2000, Inorganic chemistry.

[12]  S M Evans,et al.  Detection of hypoxia in human squamous cell carcinoma by EF5 binding. , 2000, Cancer research.

[13]  C. Koch,et al.  AN EFFECTIVE SYNTHETIC ROUTE TO EF5 , 1998 .

[14]  Hodgkiss Rj,et al.  Use of 2-nitroimidazoles as bioreductive markers for tumour hypoxia. , 1998 .

[15]  C. Anderson,et al.  REACTIONS OF THE TETRACHLOROBIS(IMIDAZOLE)RUTHENIUM(III) AND PENTACHLORO(IMIDAZOLE)RUTHENIUM(III) ANIONS WITH IMIDAZOLE AND N6,N6-DIMETHYLADENINE , 1995 .

[16]  A. Rauk,et al.  Gas and solution phase thermochemistry and transition energies of NH2• and NH3•+, and their aquo complexes: an ab initio study , 1994 .

[17]  Giovanni Luca Cascarano,et al.  Completion and refinement of crystal structures with SIR92 , 1993 .

[18]  B. Keppler,et al.  Synthesis, molecular structure, and tumor-inhibiting properties of imidazolium trans-bis(imidazole)tetrachlororuthenate(III) and its methyl-substituted derivatives , 1987 .

[19]  B. Keppler,et al.  Synthesis, antitumor activity, and X-ray structure of bis(imidazolium) (Imidazole)pentachlororuthenate(III), (ImH)2(RuImCl5) , 1987 .

[20]  P. Wardman.  Some reactions and properties of nitro radical-anions important in biology and medicine. , 1985, Environmental health perspectives.

[21]  D. L. Pavia,et al.  Introduction to Spectroscopy , 1978 .

[22]  G. Adams,et al.  Electron-Affinic SensitizationVII. A Correlation between Structures, One-Electron Reduction Potentials, and Efficiencies of Nitroimidazoles as Hypoxic Cell Radiosensitizers , 2012 .

[23]  G. Adams,et al.  Selective Activation of Drugs by Redox Processes , 1990, NATO ASI Series.

[24]  Allen J. Bard,et al.  Electrochemical Methods: Fundamentals and Applications , 1980 .

[25]  A. Gordon,et al.  The Chemist's Companion: A Handbook of Practical Data, Techniques, and References , 1972 .